[1]Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma[J]. Lancet, 1997(9084), 350:1087-1091.
[2]Li MX, Xiao ZQ, Liu YF, et al. Quantitative proteomic analysis of differential proteins in the stroma of nasopharyngeal carcinoma and normal nasopharyngeal epithelial tissue[J]. J Cell Biochem, 2009, 106(4):570-579.
[3]Kudo Y, Iizuka S, Yoshida M, et al. Periostin directly and indirectly promotes tumor lymphangiogenesis of head and neck cancer[J]. PLoS One, 2012, 7(8):e44488.
[4]Zhang Y, Zhang G, Li J, et al. The expression analysis of periostin in human breast cancer[J]. J Surg Res, 2010, 160(1):102-106.
[5]Xu D, Xu H, Ren Y, et al. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer[J]. PLoS One, 2012, 7(10):e46670.
[6]Marsh D, Suchak K, Moutasim KA, et al. Stromal features are predictive of disease mortality in oral cancer patients[J]. J Pathol, 2011, 223(4):470-481.
[7]Cheng AL, Huang WG, Chen ZC, et al. Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis[J]. Clin Cancer Res, 2008, 14(2):435-445.
[8]Wei WI, Sham JS. Nasopharyngeal carcinoma[J]. Lancet, 2005, 365(9476):2041-2054.
[9]Luo S, Zhao L, Wang J, et al. Clinical outcome for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in non-endemic region of China[J]. Head Neck, 2014, 36(6): 841-847.
[10]Deraz EM, Kudo Y, Yoshida M, et al. MMP-10/stromelysin-2 promotes invasion of head and neck cancer[J]. PLoS One, 2011, 6(10):e25438.
[11]Kim CJ, Sakamoto K, Tambe Y, et al. Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells[J]. Int J Oncol, 2011, 38(6):1759-1766.
[12]Bao S, Ouyang G, Bai X, e tal. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway[J]. Cancer Cell, 2004, 5(4):329-339.[13]Li W, Saji S, Sato F, et al. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects[J]. Int J Biol Markers, 2013, 28(2):e117-130.
[14]Ting WC, Chen LM, Pao JB, et al. Genetic polymorphisms of matrix metalloproteinases and clinical outcomes in colorectal cancer patients[J]. Int J Med Sci, 2013, 10(8):1022-1027.
[15]Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer[J]. Clin Cancer Res, 2001, 7(8):2396-2404.
[16]Singer CF, Kronsteiner N, Marton E, et al. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions[J]. Breast Cancer Res Treat, 2002, 72(1):69-77.
[17]Utispan K, Sonongbua J, Thuwajit P, et al. Periostin activates integrin alpha5beta1 through a PI3K/AKTdependent pathway in invasion of cholangiocarcinoma[J]. Int J Oncol, 2012, 41(3):1110-1118.
[18]Hwang CF, Su CY, Huang SC, et al. Low expression levels of p27 correlate with loco-regional recurrence in nasopharyngeal carcinoma[J]. Cancer Lett, 2003, 189(2):231-236.
[19]Slattery ML, John E, Torres-Mejia G, et al. Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study[J]. PLoS One, 2013, 8(5):e63165. |